Cholinesterase inhibitor use is associated with increased plasma levels of anti-Abeta 1-42 antibodies in Alzheimer's disease patients

Neuroscience Letters

Volumn 486, Issue 3, 2010, Pages 193-196

  Conti, Elisa ^a   Galimberti, Gloria ^a   Tremolizzo, Lucio ^a   Masetto, Alessandro ^a   Cereda, Diletta ^a   Zanchi, Clara ^a   Piazza, Fabrizio ^a   Casati, Marco ^a   Isella, Valeria ^a   Appollonio, Ildebrando ^a   Ferrarese, Carlo ^a  

^a SAN GERARDO HOSPITAL   (Italy)

Author keywords

AChEI; Alzheimer's disease; Anti Abeta 1 42 antibodies

Indexed keywords

AMYLOID BETA PROTEIN ANTIBODY; AMYLOID BETA PROTEIN[1-42] ANTIBODY; ANTIDEPRESSANT AGENT; DONEPEZIL; GALANTAMINE; IMMUNOGLOBULIN G; NEUROLEPTIC AGENT; PROMAZINE; QUETIAPINE; RIVASTIGMINE; UNCLASSIFIED DRUG;

ADULT; AGED; ALZHEIMER DISEASE; ANTIBODY BLOOD LEVEL; ARTICLE; CHOLINESTERASE INHIBITION; CONTROLLED STUDY; DRUG EFFECT; DRUG USE; FEMALE; HUMAN; IMMUNOMODULATION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL;

AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; AUTOANTIBODIES; CHOLINESTERASE INHIBITORS; CROSS-SECTIONAL STUDIES; FEMALE; HUMANS; MALE; MIDDLE AGED; PEPTIDE FRAGMENTS; TREATMENT OUTCOME; UP-REGULATION;

EID: 78049383757     PISSN: 03043940     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neulet.2010.09.050     Document Type: Article

References (38)

1. Bard F., Cannon C., Barbour R., Burke R.L., Games D., Grajeda H., Guido T., Hu K., Huang J., Johnson-Wood K., Khan K., Kholodenko D., Lee M., Lieberburg I., Motter R., Nguyen M., Soriano F., Vasquez N., Weiss K., Welch B., Seubert P., Schenk D., Yednock T. Peripherally administered antibodies against amyloid beta-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease. Nat. Med. 2000, 6(8):916-919.
2. Baril L., Nicolas L., Croisile B., Crozier P., Hessler C., Sassolas A., McCormick J.B., Trannoy E. Immune response to Abeta-peptides in peripheral blood from patients with Alzheimer's disease and control subjects. Neurosci. Lett. 2004, 355:226-230.
3. Bianchetti A., Ranieri P., Margiotta A., Trabucchi M. Pharmacological treatment of Alzheimer's Disease. Aging Clin. Exp. Res. 2006, 18(2):158-162.
4. Britschgi M., Olin C.E., Johns H.T., Takeda-Uchimura Y., LeMieux M.C., Rufibach K., Rajadas J., Zhang H., Tomooka B., Robinson W.H., Clark C.M., Fagan A.M., Galasko D.R., Holtzman D.M., Jutel M., Kaye J.A., Lemere C.A., Leszek J., Li G., Peskind E.R., Quinn J.F., Yesavage J.A., Ghiso J.A., Wyss-Coray T. Neuroprotective natural antibodies to assemblies of amyloidogenic peptides decrease with normal aging and advancing Alzheimer's disease. Proc. Natl. Acad. Sci. U.S.A. 2009, 106(29):12145-12150.
5. Camps P., Formosa X., Galdeano C., Gómez T., Muñoz-Torrero D., Scarpellini M., Viayna E., Badia A., Clos M.V., Camins A., Pallàs M., Bartolini M., Mancini F., Andrisano V., Estelrich J., Lizondo M., Bidon-Chanal A., Luque F.J. Novel donepezil-based inhibitors of acetyl- and butyrylcholinesterase and acetylcholinesterase-induced beta-amyloid aggregation. J. Med. Chem. 2008, 51(12):3588-3598.
6. Conti E., Galimberti G., Piazza F., Raggi M.E., Ferrarese C. Increased soluble APPalpha, Abeta 1-42 and anti-Abeta 1-42 antibodies in plasma from Down syndrome patients. Alzheimer Dis. Assoc. Disord. 2010, 24(1):96-100.
7. Deane R., Sagare K., Parisi M., LaRue B., Guo H., Wu Z., Holtzman D.M., Zlokovic B.V. IgG-assisted age-dependent clearance of Alzheimer's amyloid beta peptide by the blood-brain barrier neonatal Fc receptor. J. Neurosci. 2005, 25(50):11495-11503.
8. DeMattos R.B., Bales K.R., Cummins D.J., Dodart J.C., Paul S.M., Holtzman D.M. Peripheral anti-A beta antibody alters CNS and plasma A beta clearance and decreases brain Abeta burden in a mouse model of Alzheimer's disease. Proc. Natl. Acad. Sci. U.S.A. 2001, 98(15):8850-8855.
9. Dodel R.C., Du Y., Depboylu C., Hampel H., Frölich L., Haag A., Hemmeter U., Paulsen S., Teipel S.J., Brettschneider S., Spottke A., Nölker C., Möller H.J., Wei X., Farlow M., Sommer N., Oertel W.H. Intravenous immunoglobulins containing antibodies against beta-amyloid for the treatment of Alzheimer's disease. J. Neurol. Neurosurg. Psychiatry 2004, 75(10):1472-1474.
10. Du Y., Dodel R., Hampel H., Buerger K., Lin S., Eastwood B., Bales K., Gao F., Moeller H.J., Oertel W., Farlow M., Paul S. Reduced levels of amyloid beta-peptide antibody in Alzheimer disease. Neurology 2001, 57(5):801-805.
11. Feldman H., Gauthier S., Hecker J., Vellas B., Subbiah P., Whalen E. A 24-week, randomized, double-blind study of donepezil in moderate to severe Alzheimer's disease, donepezil MSAD study investigators group. Neurology 2001, 57(4):613-620.
12. Galimberti D, Scarpini E. Treatment of Alzheimer's disease: symptomatic and disease-modifying approaches. Curr. Aging Sci. 2010, 3(1):46-56.
13. Gustaw K.A., Garrett M.R., Lee H., Castellani R.J., Zagorski M.G., Prakasam A., Siedlak S.L., Zhu X., Perry G., Petersen R.B., Friedland R.P., Smith M.A. Antigen-antibody dissociation in Alzheimer disease: a novel approach to diagnosis. J. Neurochem. 2008, 106:1350-1356.
14. Gustaw-Rothenberg K.A., Siedlak S.L., Bonda D.J., Lerner A., Tabaton M., Perry G., Smith M.A. Dissociated amyloid-β antibody levels as serum biomarker for the progression of Alzheimer's disease: a population-based study. Exp. Gerontol. 2010, 45:52-57.
15. Hixson J.E., Vernier D.T. Restriction isotyping of human apolipoprotein E by amplification and cleavage with HhaI. J. Lipid Res. 1990, 31:545-548.
16. Hyman B.T., Smith C., Buldyrev I., Whelan C., Brown H., Tang M.X., Mayeux R. Autoantibodies to amyloid-beta and Alzheimer's disease. Ann. Neurol. 2001, 49(6):808-810.
17. Janus C., Chishti M.A., Westaway D. Transgenic mouse models of Alzheimer's disease. Biochim. Biophys. Acta 2000, 1502(1):63-75.
18. Jianping L., Zhibing Y., Wei Q., Zhikai C., Jie X., Jinbiao L. Low avidity and level of serum anti-Abeta antibodies in Alzheimer disease. Alzheimer Dis. Assoc. Disord. 2006, 20(3):127-132.
19. Kimura M., Akasofu S., Ogura H., Sawada K. Protective effect of donepezil against Abeta(1-40) neurotoxicity in rat septal neurons. Brain Res. 2005, 1047(1):72-84.
20. Lemere C.A., Masliah E. Can Alzheimer disease be prevented by amyloid- beta immunotherapy?. Nat. Rev. 2010, 6:108-119.
21. Lue L.F., Walker D.G. Modeling Alzheimer's disease immune therapy mechanisms: interactions of human postmortem microglia with antibody-opsonized amyloid beta peptide. J Neurosci. Res. 2002, 70(4):599-610.
22. McKhann G., Drachman D., Folstein M., Katzman R., Price D., Stadlan E.M. Clinical diagnosis of Alzheimer disease: report of the NINCDS-ADRDA Work Group under the auspices of department of health and human services task force on Alzheimer's disease. Neurology 1984, 34(7):939-944.
23. Nath A., Hall E., Tuzova M., Dobbs M., Jons M., Anderson C., Woodward J., Guo Z., Fu W., Kryscio R., Wekstein D., Smith C., Markesbery W.R., Mattson M.P. Autoantobodies to amyloid beta-peptide (Abeta) are increased in Alzheimer's disease patients and Abeta antibodies can enhance Abeta neurotoxicity: implications for disease pathogenesis and vaccine development. Neuromol. Med. 2003, 3:29-39.
24. Nizri E., Hamra-Amitay Y., Sicsic C., Lavon I., Brenner T. Anti-inflammatory properties of cholinergic up-regulation: a new role for acetylcholinesterase inhibitors. Neuropharmacology 2006, 50:540-547.
25. Pákáski M., Kálmán J. Interactions between the amyloid and cholinergic mechanisms in Alzheimer's disease. Neurochem. Int. 2008, 53(5):103-111.
26. Reale M., Iarlori C., Gambi F., Feliciani C., Isabella L., Gambi D. The acetylcholinesterase inhibitor, Donepezil, regulates a Th2 bias in Alzheimer's disease patients. Neuropharmacology 2006, 50(5):606-613.
27. Relkin N.R, Szabo P., Adamiak B., Burgut T., Monthe C., Lent R.W., Younkin S., Younkin L., Schiff R., Weksler M.E. 18-month study of intravenous immunoglobulin for treatment of mild Alzheimer disease. Neurobiol. Aging 2009, 30(11):1728-1736.
28. Sakono M., Zako T. Amyloid oligomers: formation and toxicity of abeta oligomers. FEBS J. 2010, 277:1348-1358.
29. Schenk D.B., Seubert P., Grundman M., Black R. Abeta immunotherapy: lessons learned for potential treatment of Alzheimer's disease. Neurodegener. Dis. 2005, 2(5):255-260.
30. Scott L.J., Goa K.L. Galantamine: a review of its use in Alzheimer's disease. Drugs 2000, 60(5):1095-1122.
31. Solomon B., Koppel R., Frankel D., Hanan-Aharon E. Disaggregation of Alzheimer beta-amyloid by site-directed mAb. Proc. Natl. Acad. Sci. U.S.A. 1997, 94(8):4109-4112.
32. Song M.S., Mook-Jung I., Lee H.J., Min J.Y., Park M.H. Serum anti-amyloid-beta antibodies and Alzheimer's disease in elderly Korean patients. J. Int. Med. Res. 2007, 35(3):301-306.
33. Szabo P., Relkin N., Weksler M.E. Natural human antibodies to amyloid beta peptide. Autoimmun. Rev. 2008, 7:415-420.
34. Taguchi H., Planque S., Nishiyama Y., Szabo P., Weksler M.E., Friedland R.P., Paul S. Catalytic antibodies to amyloid beta peptide in defense against Alzheimer disease. Autoimmun. Rev. 2008, 7(5):391-397.
35. Weksler M.E., Relkin N., Turkenich R., LaRusse S., Zhou L., Szabo P. Patients with Alzheimer disease have lower levels of serum anti-amyloid peptide antibodies than healthy elderly individuals. Exp. Gerontol. 2002, 37(7):943-948.
36. Wilcock D.M., Rojiani A., Rosenthal A., Subbarao S., Freeman M.J., Gordon M.N., Morgan D. Passive immunotherapy against Abeta in aged APP-transgenic mice reverses cognitive deficits and depletes parenchymal amyloid deposits in spite of increased vascular amyloid and microhemorrhage. J. Neuroinflam. 2004, 1:1-24.
37. Zimmermann M., Gardoni F., Marcello E., Colciaghi F., Borroni B., Padovani A., Cattabeni F., Di Luca M. Acetylcholinesterase inhibitors increase ADAM10 activity by promoting its trafficking in neuroblastoma cell lines. J. Neurochem. 2004, 90(6):1489-1499.
38. C.P. Zoia, C. Riva, V. Isella, P. Proserpio, A. Terrazzi, S. Arban, D. Salerno, V. Cassina, F. Mantegazza, L. Tremolizzo, C. Ferrarese, Non fibrillar Abeta 1-42 inhibits glutamate uptake and phosphorylates p38 in human fibroblasts, Alzheimer Dis. Assoc. Disord. in press.